Published in Clin Exp Immunol on June 01, 2015
The induction of autoimmune hepatitis in the human leucocyte antigen-DR4 non-obese diabetic mice autoimmune hepatitis mouse model. Clin Exp Immunol (2016) 0.75
Quantitation of the Rank-Rankl Axis in Primary Biliary Cholangitis. PLoS One (2016) 0.75
Deletion of Galectin-3 Enhances Xenobiotic Induced Murine Primary Biliary Cholangitis by Facilitating Apoptosis of BECs and Release of Autoantigens. Sci Rep (2016) 0.75
Dysregulation of peritoneal cavity B1a cells and murine primary biliary cholangitis. Oncotarget (2016) 0.75
B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity (2000) 15.44
CD28/B7 system of T cell costimulation. Annu Rev Immunol (1996) 10.48
Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. J Exp Med (1991) 8.78
Abrogation of TGFbeta signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease. Immunity (2000) 6.97
Cutting edge: CD28 controls peripheral homeostasis of CD4+CD25+ regulatory T cells. J Immunol (2003) 3.86
Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet (2008) 3.00
The interaction properties of costimulatory molecules revisited. Immunity (2002) 2.43
Anti-mitochondrial antibodies and primary biliary cirrhosis in TGF-beta receptor II dominant-negative mice. J Immunol (2006) 2.18
Deletion of interleukin-12p40 suppresses autoimmune cholangitis in dominant negative transforming growth factor beta receptor type II mice. Hepatology (2009) 2.11
Loss of tolerance in C57BL/6 mice to the autoantigen E2 subunit of pyruvate dehydrogenase by a xenobiotic with ensuing biliary ductular disease. Hepatology (2008) 2.05
Identification of HLA-A2-restricted CD8(+) cytotoxic T cell responses in primary biliary cirrhosis: T cell activation is augmented by immune complexes cross-presented by dendritic cells. J Exp Med (2002) 2.00
Role of CD28-B7 interactions in generation and maintenance of CD8 T cell memory. J Immunol (2001) 1.96
Deletion of interleukin (IL)-12p35 induces liver fibrosis in dominant-negative TGFβ receptor type II mice. Hepatology (2013) 1.78
CTLA4Ig: bridging the basic immunology with clinical application. Immunity (2006) 1.75
CXCR5+ CD4+ T follicular helper cells participate in the pathogenesis of primary biliary cirrhosis. Hepatology (2015) 1.70
Quantitative and functional analysis of PDC-E2-specific autoreactive cytotoxic T lymphocytes in primary biliary cirrhosis. J Clin Invest (2002) 1.65
The clinical utility of inhibiting CD28-mediated costimulation. Immunol Rev (2009) 1.58
Identification and precursor frequency analysis of a common T cell epitope motif in mitochondrial autoantigens in primary biliary cirrhosis. J Clin Invest (1998) 1.52
Adoptive transfer of CD8(+) T cells from transforming growth factor beta receptor type II (dominant negative form) induces autoimmune cholangitis in mice. Hepatology (2008) 1.45
The immunobiology and pathophysiology of primary biliary cirrhosis. Annu Rev Pathol (2013) 1.41
Mode of action of abatacept in rheumatoid arthritis patients having failed tumour necrosis factor blockade: a histological, gene expression and dynamic magnetic resonance imaging pilot study. Ann Rheum Dis (2008) 1.40
Direct CD28 costimulation is required for CD8+ T cell-mediated resistance to an acute viral disease in a natural host. J Immunol (2006) 1.34
Opposing roles of CD28:B7 and CTLA-4:B7 pathways in regulating in vivo alloresponses in murine recipients of MHC disparate T cells. J Immunol (1999) 1.33
Therapeutic effect of cytotoxic T lymphocyte antigen 4/immunoglobulin on a murine model of primary biliary cirrhosis. Hepatology (2013) 1.33
Long-term inhibition of murine lupus by brief simultaneous blockade of the B7/CD28 and CD40/gp39 costimulation pathways. J Immunol (1997) 1.29
CTLA4Ig inhibits T cell-dependent B-cell maturation in murine systemic lupus erythematosus. J Clin Invest (2000) 1.27
Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis. Arthritis Rheum (2010) 1.24
IL-12/Th1 and IL-23/Th17 biliary microenvironment in primary biliary cirrhosis: implications for therapy. Hepatology (2014) 1.15
Overexpression of microRNA-21 is associated with elevated pro-inflammatory cytokines in dominant-negative TGF-β receptor type II mouse. J Autoimmun (2013) 1.08
Shotgun proteomics: identification of unique protein profiles of apoptotic bodies from biliary epithelial cells. Hepatology (2014) 1.06
Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies. MAbs (2010) 1.06
Drug Insight: abatacept for the treatment of rheumatoid arthritis. Nat Clin Pract Rheumatol (2006) 1.04
B-cell depletion with anti-CD20 ameliorates autoimmune cholangitis but exacerbates colitis in transforming growth factor-beta receptor II dominant negative mice. Hepatology (2009) 1.03
Abatacept treatment for rheumatoid arthritis. Rheumatology (Oxford) (2010) 1.03
The indispensable role of CCR5 for in vivo suppressor function of tumor-derived CD103+ effector/memory regulatory T cells. J Immunol (2012) 1.03
CTLA4-Ig (abatacept) therapy modulates T cell effector functions in autoantibody-positive rheumatoid arthritis patients. BMC Immunol (2013) 1.03
Murine autoimmune cholangitis requires two hits: cytotoxic KLRG1(+) CD8 effector cells and defective T regulatory cells. J Autoimmun (2014) 1.02
CTLA-4-Ig therapy diminishes the frequency but enhances the function of Treg cells in patients with rheumatoid arthritis. J Clin Immunol (2011) 1.02
The immunobiology of colitis and cholangitis in interleukin-23p19 and interleukin-17A deleted dominant negative form of transforming growth factor beta receptor type II mice. Hepatology (2012) 0.98
Clonality, activated antigen-specific CD8(+) T cells, and development of autoimmune cholangitis in dnTGFβRII mice. Hepatology (2013) 0.98
Ongoing activation of autoantigen-specific B cells in primary biliary cirrhosis. Hepatology (2014) 0.98
Abatacept binds to the Fc receptor CD64 but does not mediate complement-dependent cytotoxicity or antibody-dependent cellular cytotoxicity. J Rheumatol (2007) 0.98
Environment and primary biliary cirrhosis: electrophilic drugs and the induction of AMA. J Autoimmun (2013) 0.95
Abatacept modulates human dendritic cell-stimulated T-cell proliferation and effector function independent of IDO induction. Clin Immunol (2007) 0.94
CTLA4Ig inhibits effector T cells through regulatory T cells and TGF-β. J Immunol (2013) 0.92
Co-stimulatory modulation in rheumatoid arthritis: the role of (CTLA4-Ig) abatacept. Autoimmun Rev (2008) 0.91
Mechanisms of tissue injury in autoimmune liver diseases. Semin Immunopathol (2014) 0.89
Efficacy results from pivotal clinical trials with abatacept. Clin Exp Rheumatol (2007) 0.87
Selective modulation of T-cell co-stimulation: a novel mode of action for the treatment of rheumatoid arthritis. Clin Exp Rheumatol (2009) 0.85
Breach of tolerance: primary biliary cirrhosis. Semin Liver Dis (2014) 0.83
Anti-CD40 ligand monoclonal antibody delays the progression of murine autoimmune cholangitis. Clin Exp Immunol (2013) 0.82
CTLA4Ig and the therapeutic potential of T cell co-stimulation blockade. Acta Reumatol Port (2008) 0.81
Abatacept: a costimulatory inhibitor for treatment of rheumatoid arthritis. Expert Opin Biol Ther (2005) 0.81
CTLA4-Ig preserves thymus-derived T regulatory cells. Transplantation (2014) 0.77
Endogenous interleukin-22 protects against inflammatory bowel disease but not autoimmune cholangitis in dominant negative form of transforming growth factor beta receptor type II mice. Clin Exp Immunol (2016) 0.76
Mechanisms of PTHrP-induced inhibition of smooth muscle contractility in the guinea pig gastric antrum. Neurogastroenterol Motil (2017) 0.75